Xiaomei Ma, Rong Wang, Jessica B. Long, Joseph S. Ross, Pamela R. Soulos, James B. Yu, Danil V. Makarov, Heather T. Gold and Cary P. Gross The cost implications of prostate cancer screening in the Medicare population Cancer 120
Medicare prostate cancer screening-related expenditures are substantial, vary considerably across regions, and are positively associated with rates of cancer diagnosis. Downstream procedures (biopsy, pathologic analysis, and hospitalization due to biopsy complications) account for 72% of the overall cost and are the main driver of regional variation in the cost of prostate cancer screening.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf